Yali Friedman, Publisher and Chief Editor of the Journal of Commercial Biotechnology, has an interesting and important essay on how advances in personalized medicine may have the unintended consequence of accelerating the call for US price controls – resulting in fewer new life-saving treatments.
Friedman writes:
Personalized medicine—prescription of drugs most likely to benefit and least likely to harm individual or groups of patients—promises welcome positive changes to healthcare. It may, however, also have negative sequelae originating from incompatibilities with the current healthcare delivery system and the need for regulatory and policy changes to accommodate personalized medicine.
His full article, Will personalized medicine be a driver for widespread price controls, can be found here.
